CytoSorbents Announces the REFRESH 2-AKI Trial Data Monitoring Committee Has Recommended Study Resumption Following Favorable Review of Safety Data
Stock Information for CytoSorbents Corporation
Loading
Please wait while we load your information from QuoteMedia.